{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:18:31Z","timestamp":1779880711287,"version":"3.53.1"},"reference-count":30,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Ifosfamide is used to treat soft-tissue sarcoma (STS) and bone sarcoma (BS), with improved efficacy at doses above 9 g\/m2\/cycle. To mitigate treatment-associated toxicity with higher doses, continuous infusional ifosfamide is increasingly used. However, clinical outcome data remain limited. Single-centre retrospective analysis of patients treated with four-weekly infusional ifosfamide (14 g\/m2\/14d) between August 2012 and February 2019 was conducted. Radiological response, progression-free survival (PFS), overall survival (OS) and toxicity were evaluated. Eighty patients were treated\u201446 with STS and 34 with BS. Patients received a median of three cycles of infusional ifosfamide (1\u201324). Overall disease control rate (DCR) in STS was 50% (23 of 46 patients), with a median PFS of 3.8 months, and median OS of 13.0 months. In synovial sarcoma (SS), DCR was 80% (12\/15), median PFS 8.1 months and median OS 20.9 months. Overall DCR in BS (34 patients) was 30%, with a median PFS of 2.5 months and median OS of 6.2 months. Five patients (6%) stopped treatment due to toxicity alone within the first two cycles. A further 10 patients stopped treatment due to toxicity during later treatment cycles (12%) and 18 patients (23%) required dose modification. Forty-five patients (56%) experienced grade (G) 3\/4 haematological toxicity, with 12 episodes of febrile neutropenia and one treatment-related death. Twenty-seven patients (34%) experienced G3\/4 non-haematological toxicity, most commonly nausea and vomiting (10, 13%). In summary, infusional ifosfamide has efficacy in STS, most notable in SS. Benefit appears limited in BS. Treatment is associated with toxicity that requires specialist supportive care.<\/jats:p>","DOI":"10.3390\/cancers12113408","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T11:02:12Z","timestamp":1605610932000},"page":"3408","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Continuous 14 Day Infusional Ifosfamide for Management of Soft-Tissue and Bone Sarcoma: A Single Centre Retrospective Cohort Analysis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0146","authenticated-orcid":false,"given":"Thomas J.","family":"Carter","sequence":"first","affiliation":[{"name":"London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Milic","sequence":"additional","affiliation":[{"name":"London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"McDerra","sequence":"additional","affiliation":[{"name":"London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"McTiernan","sequence":"additional","affiliation":[{"name":"London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahbubl","family":"Ahmed","sequence":"additional","affiliation":[{"name":"London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Karavasilis","sequence":"additional","affiliation":[{"name":"London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Michelagnoli","sequence":"additional","affiliation":[{"name":"London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Windsor","sequence":"additional","affiliation":[{"name":"London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Seddon","sequence":"additional","affiliation":[{"name":"London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Whelan","sequence":"additional","affiliation":[{"name":"London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palma","family":"Dileo","sequence":"additional","affiliation":[{"name":"London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8328-0260","authenticated-orcid":false,"given":"Sandra J.","family":"Strauss","sequence":"additional","affiliation":[{"name":"London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK"},{"name":"Research Department of Oncology, UCL Cancer Institute, 70 Huntley Street, London WC1E 6BT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1634\/theoncologist.12-11-1351","article-title":"The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas","volume":"12","author":"Tascilar","year":"2007","journal-title":"Oncologist"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/CCO.0000000000000301","article-title":"First-line treatment in advanced or metastatic disease: One size fits all or adapted to specific histiotypes?","volume":"28","author":"Seddon","year":"2016","journal-title":"Curr. Opin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","article-title":"Ewing Sarcoma: Current Management and Future Approaches Through Collaboration","volume":"33","author":"Gaspar","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma: Current Treatment and a Collaborative Pathway to Success","volume":"33","author":"Isakoff","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0140-6736(90)90053-8","article-title":"Ifosfamide by continuous infusion to prevent encephalopathy","volume":"335","author":"Cerny","year":"1990","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1023\/A:1008279426654","article-title":"Phase II study of continuous-infusion high-dose ifosfamide in advanced and\/or metastatic pretreated soft tissue sarcomas","volume":"8","author":"Palumbo","year":"1997","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.25259\/IJMIO_21_2019","article-title":"Is continuous infusion of high-dose ifosfamide, a safe option? Drug review","volume":"5","author":"Gharote","year":"2020","journal-title":"Int. J. Mol. Immuno Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Perego, G., Gregis, F., Rossi, L., Mazzoleni, M., Nozza, S., Nozza, R., and Gatti, V.P. (2020). Continuous-infusion and outpatient setting: A chance for patients, a challenge for hospital pharmacists. J. Oncol. Pharm. Pract.","DOI":"10.1177\/1078155220937389"},{"key":"ref_10","first-page":"179","article-title":"Ifosfamide and mesna","volume":"9","author":"Schoenike","year":"1990","journal-title":"Clin. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/ckj\/sfaa017","article-title":"The growing pains of ifosfamide","volume":"13","author":"Sprangers","year":"2020","journal-title":"Clin. Kidney J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2006.09.7717","article-title":"Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study","volume":"25","author":"Lorigan","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_13","first-page":"868973","article-title":"Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma","volume":"2013","author":"Alam","year":"2013","journal-title":"Sarcoma"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2045-3329-4-16","article-title":"High-dose continuous-infusion ifosfamide in advanced well-differentiated\/dedifferentiated liposarcoma","volume":"4","author":"Sanfilippo","year":"2014","journal-title":"Clin. Sarcoma Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000328795","article-title":"High-Dose Ifosfamide as Second- or Third-Line Chemotherapy in Refractory Bone and Soft Tissue Sarcoma Patients","volume":"80","author":"Lee","year":"2011","journal-title":"Oncology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10596","DOI":"10.1200\/jco.2014.32.15_suppl.10596","article-title":"14-day continuous infusion ifosfamide in advanced refractory sarcomas","volume":"32","author":"Singh","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/COC.0000000000000243","article-title":"Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma","volume":"41","author":"Noujaim","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/CCO.0b013e32834796e6","article-title":"Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma","volume":"23","author":"Crago","year":"2011","journal-title":"Curr. Opin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10434-999-0389-5","article-title":"Myxoid liposarcoma\u2014Frequency and the natural history of nonpulmonary soft tissue metastases","volume":"6","author":"Spillane","year":"1999","journal-title":"Ann. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1148\/radiol.2512081403","article-title":"High-Grade Soft-Tissue Sarcomas: Tumor Response Assessment\u2014Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria","volume":"251","author":"Stacchiotti","year":"2009","journal-title":"Radiology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JOP.2015.009944","article-title":"Chemotherapy for Bone Sarcoma in Adults","volume":"12","author":"Wagner","year":"2016","journal-title":"J. Oncol. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/pbc.22596","article-title":"Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: Feasibility and efficacy in refractory pediatric sarcoma","volume":"55","author":"Meazza","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_24","unstructured":"Seddon, B.M., McTiernan, A.M., Michelagnoli, M.P., Gabbie, S., Daw, S., and Whelan, J.S. (2005, January 14\u201317). High-dose ifosfamide in relapsed or progressive Ewing\u2019s sarcoma. Proceedings of the Sarcoma Meeting Stuttgart, Stuttgart, Germany. Sarcoma, March\/June 2005."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pbc.21917","article-title":"Response to high-dose ifosfamide in patients with advanced\/recurrent Ewing sarcoma","volume":"52","author":"Ferrari","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11502","DOI":"10.1200\/JCO.2020.38.15_suppl.11502","article-title":"Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES)","volume":"38","author":"McCabe","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF01240320","article-title":"6-day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies","volume":"123","author":"Mita","year":"1997","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Palmerini, E., Setola, E., Grignani, G., D\u2019Ambrosio, L., Comandone, A., Righi, A., Longhi, A., Cesari, M., Paioli, A., and Hakim, R. (2020). High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series. Cells, 9.","DOI":"10.3390\/cells9112389"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_30","unstructured":"Authority, H.R. (2020, November 16). Defining Research\u2014National Research Ethics Service Guidance to Help You Decide If Your Project Requires Review by a Research Ethics Committee. April 2013. Available online: http:\/\/www.hra-decisiontools.org.uk."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3408\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:34:39Z","timestamp":1760178879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["cancers12113408"],"URL":"https:\/\/doi.org\/10.3390\/cancers12113408","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,17]]}}}